AU2006328198B2 - Substituted phenol derivatives as analgesics - Google Patents

Substituted phenol derivatives as analgesics Download PDF

Info

Publication number
AU2006328198B2
AU2006328198B2 AU2006328198A AU2006328198A AU2006328198B2 AU 2006328198 B2 AU2006328198 B2 AU 2006328198B2 AU 2006328198 A AU2006328198 A AU 2006328198A AU 2006328198 A AU2006328198 A AU 2006328198A AU 2006328198 B2 AU2006328198 B2 AU 2006328198B2
Authority
AU
Australia
Prior art keywords
glycine
receptors
compound
compounds
chloropropofol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006328198A
Other languages
English (en)
Other versions
AU2006328198A1 (en
Inventor
Delia Belelli
Gertrud Haeseler
Jeremy Lambert
Martin Leuwer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hannover Medical School
University of Liverpool
University of Dundee
Original Assignee
Hannover Medical School
University of Liverpool
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannover Medical School, University of Liverpool, University of Dundee filed Critical Hannover Medical School
Publication of AU2006328198A1 publication Critical patent/AU2006328198A1/en
Application granted granted Critical
Publication of AU2006328198B2 publication Critical patent/AU2006328198B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006328198A 2005-12-19 2006-12-19 Substituted phenol derivatives as analgesics Ceased AU2006328198B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75155905P 2005-12-19 2005-12-19
US60/751,559 2005-12-19
US79627006P 2006-04-27 2006-04-27
US60/796,270 2006-04-27
PCT/GB2006/004762 WO2007071967A2 (en) 2005-12-19 2006-12-19 Substituted phenol derivatives as analgesics

Publications (2)

Publication Number Publication Date
AU2006328198A1 AU2006328198A1 (en) 2007-06-28
AU2006328198B2 true AU2006328198B2 (en) 2013-07-18

Family

ID=37909696

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006328198A Ceased AU2006328198B2 (en) 2005-12-19 2006-12-19 Substituted phenol derivatives as analgesics

Country Status (6)

Country Link
US (2) US20070142477A1 (enExample)
EP (1) EP1965780B1 (enExample)
JP (1) JP5537033B2 (enExample)
AU (1) AU2006328198B2 (enExample)
CA (1) CA2632561C (enExample)
WO (1) WO2007071967A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5537033B2 (ja) * 2005-12-19 2014-07-02 ザ ユニヴァーシティー オブ リヴァプール 無痛覚
WO2008141097A2 (en) * 2007-05-09 2008-11-20 Pharmacofore, Inc. Stereoisomers propofol therapeutic compounds
RU2470907C2 (ru) * 2007-05-09 2012-12-27 Сигничер Терапьютикс, Инк. Терапевтические соединения
GB0822486D0 (en) 2008-12-10 2009-01-14 Univ Liverpool Compounds for use in the treatment of pain
US20130005718A1 (en) * 2009-08-11 2013-01-03 Tibbs Gareth R Compositions and methods of treating chronic pain by administering propofol derivatives
CN103896743B (zh) * 2012-12-28 2017-04-05 四川海思科制药有限公司 一种2，6‑二异丙基‑4‑氟苯酚的制备方法
GB201322905D0 (en) 2013-12-23 2014-02-12 Univ Liverpool Pharmacologically active compounds
US10449198B2 (en) 2016-07-01 2019-10-22 The University Of Liverpool Method for treating pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707849A1 (en) * 1994-02-08 1996-04-24 Bobel246 S.L. Use of derivatives of 2,4-bisubstituted phenols as 5-lipoxigenase inhibitors
WO2005033279A2 (en) * 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
WO2007009606A2 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel enthaltend eine kombination biozider und ein keratolytikum

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518315B1 (en) * 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
WO2000054588A1 (en) * 1999-03-15 2000-09-21 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
NZ525917A (en) * 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US20040038874A1 (en) * 2002-08-22 2004-02-26 Osemwota Omoigui Method of treatment of persistent pain
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
JP5537033B2 (ja) * 2005-12-19 2014-07-02 ザ ユニヴァーシティー オブ リヴァプール 無痛覚

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707849A1 (en) * 1994-02-08 1996-04-24 Bobel246 S.L. Use of derivatives of 2,4-bisubstituted phenols as 5-lipoxigenase inhibitors
WO2005033279A2 (en) * 2003-09-29 2005-04-14 University Of Virginia Patent Foundation Discovery of novel soluble crystalline anesthetics
WO2007009606A2 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel enthaltend eine kombination biozider und ein keratolytikum
AU2006272087A1 (en) * 2005-07-19 2007-01-25 Lanxess Deutschland Gmbh Disinfecting agent containing a combination of biocidal phenols and a keratolytic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology (2005) Vol.145 pp 916-925 *
European Journal of Anaesthesiology (2002) 19(1) pp 1-8 *

Also Published As

Publication number Publication date
EP1965780B1 (en) 2017-03-08
WO2007071967A3 (en) 2007-10-11
US20070142477A1 (en) 2007-06-21
CA2632561C (en) 2015-01-27
US20160095823A1 (en) 2016-04-07
JP2009520010A (ja) 2009-05-21
AU2006328198A1 (en) 2007-06-28
CA2632561A1 (en) 2007-06-28
EP1965780A2 (en) 2008-09-10
WO2007071967A2 (en) 2007-06-28
JP5537033B2 (ja) 2014-07-02

Similar Documents

Publication Publication Date Title
US20160095823A1 (en) Methods of using propofol derivatives for analgesia
Merlos et al. Pharmacological modulation of the sigma 1 receptor and the treatment of pain
Martina et al. The sigma‐1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus
Martel et al. In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death
Wei et al. Presynaptic mechanisms and KCNQ potassium channels modulate opioid depression of respiratory drive
Huang et al. Bilobalide, a sesquiterpene trilactone from Ginkgo biloba, is an antagonist at recombinant α1β2γ2L GABAA receptors
Urban et al. In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue
JPH11509844A5 (enExample)
Wu et al. A mibefradil metabolite is a potent intracellular blocker of L-type Ca2+ currents in pancreatic β-cells
Demir et al. Modulation of glycine receptor function by the synthetic cannabinoid HU210
US8507724B2 (en) Compounds for use in the treatment of pain
WO2007016190A2 (en) Antiparkinsonian action of phenylisopropylamines
US20030181426A1 (en) Compositions and methods for treating pain using cyclooxygenase-1 inhibitors
Plazas et al. Inhibition of the α9α10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors
Leiva et al. Pharmacological and electrophysiological characterization of novel NMDA receptor antagonists
Sadek et al. Phenylalanine derivatives with modulating effects on human α1-glycine receptors and anticonvulsant activity in strychnine-induced seizure model in male adult rats
Köfalvi Alternative interacting sites and novel receptors for cannabinoid ligands
Lynch et al. Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 KATP channels
Boulain et al. L‐DOPA and 5‐HTP modulation of air‐stepping in newborn rats
Puja et al. Modulation of NMDA receptor activity by CR4056, an imidazoline-2 receptor ligand with analgesic properties
Mela et al. Group-II metabotropic glutamate receptors negatively modulate NMDA transmission at striatal cholinergic terminals: role of P/Q-type high voltage activated Ca++ channels and endogenous dopamine
Lau et al. Alfaxalone causes reduction of glycinergic IPSCs, but not glutamatergic EPSCs, and activates a depolarizing current in rat hypoglossal motor neurons
Haeseler et al. Structural features of phenol derivatives determining potency for activation of chloride currents via α1 homomeric and α1β heteromeric glycine receptors
Lopes-Azevedo et al. Central mechanism of the cardiovascular responses caused by L-proline microinjected into the paraventricular nucleus of the hypothalamus in unanesthetized rats
De La Roche et al. Paracetamol fails to positively modulate and directly activate chloride currents in human α1-glycine receptors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired